Exploratory activity-based direct cost analysis of robotic platforms in urologic surgery
Authors:
Open Access
- 19 June 2026
- journal article
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1)
Abstract
Robotic-assisted surgery has become increasingly widespread across surgical specialties over the last two decades. However, the high costs associated with robotic systems remain a major limitation to their diffusion. Recently introduced robotic platforms aim to increase market competition and potentially reduce procedural costs. This study evaluated the direct in-hospital costs associated with three robotic platforms in urologic surgery. A retrospective single-center cost analysis was conducted on robotic-assisted procedures performed in 2023. A total of 284 robotic-assisted radical prostatectomies (RALP) were included (200 Da Vinci, 77 Hugo™ RAS, and 7 Versius ® ), while 77 robotic-assisted partial nephrectomies were analyzed (57 Da Vinci and 20 Hugo™ RAS). Partial nephrectomy analysis therefore involved only two platforms. Cost estimation was performed using an activity-based costing approach from the hospital/provider perspective, including direct costs related to robotic equipment, maintenance, consumables, operating room occupancy, personnel, and hospitalization. For partial nephrectomy, no statistically significant difference in total direct cost was observed between Da Vinci (€7856.89 ± 1335.76) and Hugo™ (€8226.36 ± 1481.85) platforms ( p = 0.16), although operating room time and related costs were significantly higher with Hugo™ ( p = 0.03 and p = 0.04, respectively). For RALP, mean total costs were €8077.99 (Da Vinci), €7867.92 (Hugo™), and €8430.76 (Versius ® ), without statistically significant differences ( p = 0.13). Operative and operating room times were significantly longer with Versius ® ( p < 0.05). Due to the limited number of Versius ® procedures, findings involving this platform should be considered exploratory. In this single-center experience, direct in-hospital costs associated with robotic-assisted urologic procedures appeared broadly comparable across platforms. However, findings should be interpreted cautiously given the retrospective design, unbalanced cohorts, absence of detailed case-mix adjustment, and the limited Versius ® sample size.Keywords
Funding Information
- Politecnico di Milano
This publication has 22 references indexed in Scilit:
- Robot-assisted Radical Prostatectomy with the Hugo RAS and da Vinci Surgical Robotic Systems: A Systematic Review and Meta-analysis of Comparative StudiesEuropean Urology Focus, 2024
- Perioperative, functional, and oncological outcomes of Da Vinci vs. Hugo RAS for robot‑assisted radical prostatectomy: evidence based on controlled studiesJournal of Robotic Surgery, 2024
- Safety and feasibility of “three arms settings” robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case seriesWorld Journal of Urology, 2024
- Cost analysis of new robotic competitors: a comparison of direct costs for initial hospital stay between Da Vinci and Hugo RAS for radical prostatectomyJournal of Robotic Surgery, 2024
- Da Vinci vs. Hugo RAS for robot-assisted radical prostatectomy: a prospective comparative single-center studyWorld Journal of Urology, 2024
- Operative efficiency: a comparative analysis of Versius and da Vinci robotic systems in abdominal surgeryJournal of Robotic Surgery, 2024
- Transition from da Vinci to Versius robotic surgical system: initial experience and outcomes of over 100 consecutive proceduresJournal of Robotic Surgery, 2022
- Objective assessment of robotic surgical skills: review of literature and future directionsSurgical Endoscopy, 2022
- Past, present and future of surgical roboticsTrends in Urology & Men's Health, 2022
- Worldwide diffusion of robotic approach in general surgeryUpdates in Surgery, 2021